Methods for Treating Cancer
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2022/033255, filed Jun 13, 2022. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,897,871 | Methods for Treating Cancer In force · High confidence UsedRemaining | Scorpion Therapeutics, Inc. | In force | High confidence | ||
| US 12,084,434 | Methods for Treating Cancer In force · High confidence | Scorpion Therapeutics, Inc. | In force | High confidence | ||
| US 12,312,341 | Methods for Treating Cancer In force · High confidence | Scorpion Therapeutics, Inc. | In force | High confidence | ||
| Application 18/568,899 | Urea Derivatives Which Can Be Used to Treat Cancer Pending Not granted | Scorpion Therapeutics, Inc. | Pending | Not granted | ||
| Application 19/187,369 | Methods for Treating Cancer Pending Not granted | Scorpion Therapeutics, Inc. | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Scorpion Therapeutics, Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.